VPT:CC - Ventripoint Diagnostics to Attend 8th World Congress of Paediatric Cardiology and Cardiac Surgery
(TheNewswire)
Toronto, Ontario – The Newswire –August 2, 2023 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) is thrilled to announce that it will be attendingthe 8 th World Congress of Paediatric Cardiology and Cardiac Surgeryin Washington, DC. This is the first time the congress will be held inthe continental United States. The conference will run from August27 th , 2023 – September 1 st , 2023, inWashington DC.
“We are looking forward to this great event toshowcase our AI empowered technology and products in the treatment andmonitoring of congenital heart conditions and disease. We continue tobuild awareness of our products through these types of engagements;they are key to getting our product in front of clinicians so thatthey can see the power of the VMS+ products in elevating the cardiaccare that they provide to their patients”, said Dr. AlviraMacanovic, President and CEO of Ventripoint Diagnostics.
The World Congress is typically held every four yearsand brings together over 4,500 participants comprised of internationalleaders in paediatric cardiology, cardiac surgery, cardiac intensivecare, and other topics. The conference will be focused on congenitalheart disease, echocardiography, pulmonary hypertension, big data, newtechnology and artificial intelligence.
The scientific program is interdisciplinary and hasbeen developed by leaders in all disciplines of paediatric cardiaccare. A program of unparalleled breadth and depth features 22subspecialty tracks designed so professionals from all disciplines cancustomize their learning experience, based on their ownneeds.
More than 1,500 scientific posters will showcase thelatest science. An interactive Multi-dimensional Anatomy Lab willshowcase the evolution of cardiac imaging and a Digital TransformationHub will showcase advanced technology that can be integrated intocardiovascular practice to drive innovative care. As an attendee of this prestigious event, Ventripoint willhave the opportunity to engage with professionals in the paediatriccardiology field, as well as our distributors to continue to build ourglobal network.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe, and Canada.
For further information, pleasecontact:
Jonathan Robinson CFA
(416) 669-1001
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2023 TheNewswire - All rights reserved.